← Back to Clinical Trials
Recruiting NCT07059663

NCT07059663 Synergic Effects of Schroth Method With and Without Core Stabilization Exercises in Idiopathic Scoliosis Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07059663
Status Recruiting
Phase
Sponsor University of Lahore
Condition Scoliosis
Study Type INTERVENTIONAL
Enrollment 72 participants
Start Date 2025-07-30
Primary Completion 2025-09-10

Eligibility & Interventions

Sex All sexes
Min Age 10 Years
Max Age 18 Years
Study Type INTERVENTIONAL
Interventions
Schroth Method with Core Stabilization ExercisesSchroth Method

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 72 participants in total. It began in 2025-07-30 with a primary completion date of 2025-09-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

A randomized controlled trial was conducted on 72 patients diagnosed with idiopathic scoliosis at the University of Lahore Teaching Hospital. The study aimed to explore the synergistic effects of the Schroth method with and without core stabilization exercises. Participants were randomly allocated into two groups: Group A, which received both the Schroth method and core stabilization exercises, and Group B, which received only the Schroth method. The intervention lasted for 10 weeks, with assessments conducted at baseline, the 5th week, and the 10th week. Outcome measures included Cobb angle (spinal curvature), lumbar extensor endurance (Sorensen test), chest mobility, and quality of life (SRS-22 questionnaire). The study found significant improvements in all outcome measures for both groups, with Group A showing superior results. The addition of core stabilization exercises to the Schroth method resulted in better reductions in Cobb angle, enhanced lumbar extensor endurance, and improved chest mobility and quality of life, indicating a synergistic effect of the combined approach. The findings suggest that incorporating core stabilization exercises into scoliosis treatment protocols can lead to superior clinical outcomes.

Eligibility Criteria

Inclusion Criteria: * • Age 10 to 18 * X-ray diagnosed of idiopathic scoliosis with Cobb Angle 10˚- 30˚ * Participants with Idiopathic Scoliosis * Both genders will be included * Scoliosis with Down syndrome. Exclusion Criteria: * Any neurological condition such as cerebral palsy or epilepsy. * Any other orthopedic condition such as hip dysplasia, osteogenesis imperfecta, or leg length discrepancy. * Surgical history of the spine, such as spinal fusion and decompression surgery. * Severe systemic disorders such as autoimmune disorders, severe cardiovascular conditions * Non-Idiopathic Scoliosis

Contact & Investigator

Central Contact

Dr Asim Arif, Physical Therapist

✉ asim.arif@uipt.uol.edu.pk

📞 +923216597727

Frequently Asked Questions

Who can join the NCT07059663 clinical trial?

This trial is open to participants of all sexes, aged 10 Years or older, up to 18 Years, studying Scoliosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07059663 currently recruiting?

Yes, NCT07059663 is actively recruiting participants. Contact the research team at asim.arif@uipt.uol.edu.pk for enrollment information.

Where is the NCT07059663 trial being conducted?

This trial is being conducted at Lahore, Pakistan.

Who is sponsoring the NCT07059663 clinical trial?

NCT07059663 is sponsored by University of Lahore. The trial plans to enroll 72 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology